The Hematti Laboratory
Faculty > Peiman Hematti
Peiman Hematti
Associate Professor, Medicine, Pediatrics, Surgery & Biomedical Engineering
pxh@medicine.wisc.edu
Organ System/Disease Focus
Hematopoietic (blood) system; Treatment of hematological malignancies through hematopoietic stem cell transplantation; Immunology of transplantation
Aligned Research Focus
Bone marrow (hematopoietic and mesenchymal) stem cell biology
Research Description
Peiman Hematti, MD is Associate Professor of Medicine in section of Hematology/Oncology, UW-Madison School of Medicine and Public Health, with joint appointments in departments of pediatrics, surgery and biomedical engineering. He is director of Clinical Hematopoietic Cell Processing Laboratory, and medical director of Hematopoietic Cell Collection facility at University of Wisconsin Hospital and Clinics, overseeing bone marrow and stem cell collections, and processing procedures for hematopoietic cell transplantation or other cellular therapy applications at UW-Madison Hospital and Clinics. In addition to participating in clinical care of bone marrow stem cell transplant patients Dr. Hematti is a collaborator on many novel cellular therapy clinical trials. His clinical research interest is in the use of mesenchymal stem cells for treatment of graft versus host disease and other post-transplant immunological complications, novel cellular therapies for cancer treatment, and use of bone marrow stem cells in regenerative medicine.
Dr. Hematti's laboratory research focuses on immunobiology of stem cell transplantation with a special focus on investigating the immunomodulatory and anti-inflammatory properties of mesenchymal stem cells. He is collaborating with many investigators on the UW-campus studying the potential of mesenchymal stem cells in many different pre-clinical models. As co-principal investigator of UW-Madison Production Assistance for Cellular Therapy (PACT) award sponsored by NHLBI, NIH he is also actively involved in many bench to bedside research activities with the goal of moving cellular therapies towards clinical trials.
Selected References
Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, Holt IE, Eckfeldt CE, Sharma Y, Schmidt M, von Kalle C, Persons DA, Billings EM, Verfaillie CM, Nienhuis AW, Wolfsberg TG, Dunbar CE, Calmels B. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2(12):e423, 2004.
Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in non-human primates. Blood 107(9): 3772-3778, 2006.
Trivedi P, Hematti P., Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells, Exp Hematol. 2008 Mar;36(3):350-9.
Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Experimental Hematology 37(12):1445-53, 2009.
Hanson SE, King, SN, Kim J, Chen X, Thibeault SL, Hematti P. The effect of mesenchymal stromal cell – hyaluronic acid hydrogel constructs on immunophenotype of macrophages.Tissue Eng Part A. 2011 Oct;17(19-20):2463-71.